| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2026 1.989.a | Amgros I/S | Otsuka Pharma Scandinavia AB | 97.400.000 kr. | 8. september 2026 |